Notícias

With a 5-year average dividend growth rate of 42.4%, The Cigna Group (NYSE:CI) is included among the 14 Best Dividend Stocks to Buy for Steady Growth. On May 5, Bernstein analyst Lance Wilkes raised the firm’s price recommendation on The Cigna Group (NYSE:CI) to $371 from $358. It reiterated an Outperform rating following the company’s quarterly […]

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...

Insight into Chris Davis (Trades, Portfolio)'s Strategic Moves in Q1 2026

The most significant insight currently obscured by CVS Health's (CVS) headline revenue growth is a high-stakes transition: the company is attempting to use a temporary surge in insurance profitability to outrun the structural margin pressures facing its pharmacy benefit management (PBM) business.

Investors were underwhelmed by the solid earnings posted by The Cigna Group ( NYSE:CI ) recently. Our analysis says...

With an upside potential of 20.18% as of May 3, The Cigna Group (NYSE:CI) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. The Cigna Group (NYSE:CI) is a global health company that provides insurance and related products and services. It operates through two segments: Evernorth Health Services and Cigna Healthcare. […]

CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.

Shares of health insurance company Cigna (NYSE:CI) fell 2.5% in the afternoon session after the company announced it will exit the Affordable Care Act (ACA) marketplace in 2027, which overshadowed a strong first-quarter earnings report.

Investors in The Cigna Group ( NYSE:CI ) had a good week, as its shares rose 2.6% to close at US$283 following the...

Health insurance company Cigna (NYSE:CI) announced better-than-expected revenue in Q1 CY2026, with sales up 4.7% year on year to $68.52 billion. Its non-GAAP profit of $7.79 per share was 2.4% above analysts’ consensus estimates.

The Cigna Group (NYSE:CI) reported a strong start to 2026 and raised its full-year adjusted earnings outlook following first-quarter results that management said exceeded expectations in key areas, while also announcing additional portfolio changes and providing an update on its leadership transitio

Moby summary of Cigna Corporation's Q1 2026 earnings call

CI beats Q1 EPS estimates as Evernorth revenues jump 9% despite rising pharmacy costs; 2026 EPS outlook lifted to at least $30.35.

Cigna raises 2026 profit outlook after a first-quarter beat, while exiting ACA plans and reviewing EviCore strategic options.

The move follows Aetna’s departure from the ACA market, which has seen significantly declining membership amid rising premium bills.

Is CI a good stock to buy? We came across a bullish thesis on The Cigna Group on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on CI. The Cigna Group’s share was trading at $279.92 as of April 20th. CI’s trailing and forward P/E were 12.62 and 9.23, respectively according to Yahoo Finance. […]

While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The company modestly raised its forecast for 2026 profits amid a shift in its drug pricing and CEO transition.